Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Argon Plasma Coagulation in the Treatment of Patients With Hemoptysis Caused by Endobronchial Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with hemoptysis caused by endobronchial (i.e. identifiable with flexible bronchoscopy) malignancies, without coagulopathy or other medically correctable causes of bleeding, who need endoscopic intervention with Argon Plasma Coagulation to stop bleeding~* Adult patients who are able to tolerate bronchoscopy~* Adult patients who are able to sign the written informed consent for the study participation~Exclusion Criteria:~* Patients with hemoptysis caused by endobronchial malignancies with coagulopathy or other medically correctable causes of bleeding.~* Patients who are not able to tolerate bronchoscopy~* Patients with hemoptysis without identifiable endobronchial malignancies during flexible bronchoscopy~* Patients with Pace-Maker and/or Automated Implantable Cardioverter- Defibrillator(AICD)~* Patients who refuse/are not able to sign the informed consent for the study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemoptysis patients (Type: None): Hemoptysis patients caused by endobronchial malignancies

Based on this trial design, predict the completion outcome and termination type (if applicable).